Advantage Alpha Capital Partners LP Puma Biotechnology, Inc. Call Options Transaction History
Advantage Alpha Capital Partners LP
- $419 Million
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PBYI
# of Institutions
101Shares Held
29MCall Options Held
50.6KPut Options Held
16.3K-
Vanguard Group Inc Valley Forge, PA3.64MShares$10.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$10.7 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.06MShares$9.19 Million0.42% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.88MShares$8.64 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.97MShares$5.91 Million0.02% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $137M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...